Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diagnosticos da AmericaBSP:DASA3 -1.14%46 EV-to-EBITDA is 5.07 as of Aug. 02, 2026, which is 62% below its 10-year median of 13.27. GuruFocus rates BSP:DASA3 with a GF Score™ of 46/100 and a GF Value™ of R$1.68 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 119 Medical Diagnostics & Research companies, Diagnosticos da America ranks better than 86.55% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Diagnosticos da America's enterprise value is R$9,724 Mil.
Diagnosticos da America's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was R$1,916 Mil. Therefore, Diagnosticos da America's EV-to-EBITDA for today is 5.07.
The historical rank and industry rank for Diagnosticos da America's EV-to-EBITDA or its related term are showing as below:
BSP:DASA3'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.96 Med: 13.27 Max: 106.88
Current: 5.08
During the past 13 years, the highest EV-to-EBITDA of Diagnosticos da America was 106.88. The lowest was 3.96. And the median was 13.27.
BSP:DASA3's EV-to-EBITDA is ranked better than 86.55% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.06
vs BSP:DASA3: 5.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Diagnosticos da America (BSP:DASA3) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diagnosticos da America's PE Ratio (TTM) for today is calculated as:
Diagnosticos da America's share price for today is R$2.61.
Diagnosticos da America's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-0.832.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:DASA3 vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Diagnosticos da America's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnosticos da America EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diagnosticos da America's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Diagnosticos da America's EV-to-EBITDA falls into.
Diagnosticos da America's current Enterprise Value is R$9,724 Mil.
Diagnosticos da America's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,916 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnosticos da America (BSP:DASA3) has a EV-to-EBITDA of 5.07 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Diagnosticos da America. This is 62% below median its historical median of 13.27. Over the past decade, Diagnosticos da America's EV-to-EBITDA has ranged from 3.96 to 106.88. According to the industry distribution chart, Diagnosticos da America ranks #16 out of 119 companies in the Medical Diagnostics & Research industry, placing it in the top 13.4%.
Is Diagnosticos da America's EV-to-EBITDA too high?
Diagnosticos da America's current EV-to-EBITDA of 5.07 is 62% below median its 10-year median of 13.27. Over the past 10 years, this metric has ranged from a low of 3.96 to a high of 106.88. The Medical Diagnostics & Research industry median EV-to-EBITDA is 15.06. Diagnosticos da America's value of 5.07 is 66.3% below this industry median. Based on the distribution chart, Diagnosticos da America ranks #16 out of 119 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Diagnosticos da America has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnosticos da America's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnosticos da America ranks #16 out of 119 companies for EV-to-EBITDA. This places Diagnosticos da America in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 15.06. Diagnosticos da America's value of 5.07 is 66.3% below this benchmark. Historically, Diagnosticos da America's own EV-to-EBITDA has ranged from 3.96 to 106.88 over the past decade. While the company's 10-year median is 13.27 vs. the industry median of 15.06, Diagnosticos da America has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.06, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnosticos da America's current EV-to-EBITDA of 5.07 is 66.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Diagnosticos da America. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnosticos da America's current EV-to-EBITDA is 5.07, which is 62% below median its own 10-year median of 13.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnosticos da America stock overvalued right now?
Based on GuruFocus' analysis, Diagnosticos da America (BSP:DASA3) is currently considered Significantly Overvalued. The stock's GF Value™ is R$1.68, compared to a current price of R$2.61 — trading 55.4% above its estimated fair value. The current EV-to-EBITDA is 5.07, which is 62% below median its 10-year median of 13.27 and 66.3% below the Medical Diagnostics & Research industry median of 15.06. Diagnosticos da America's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Diagnosticos da America (BSP:DASA3), the current EV-to-EBITDA is 5.07 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diagnosticos da America (BSP:DASA3) Overvalued in 2026?
Based on GuruFocus' analysis, Diagnosticos da America stock appears to be overvalued.
The current stock price of R$2.61 is trading 55.4% above its estimated GF Value™ of R$1.68.
GuruFocus considers Diagnosticos da America to be Significantly Overvalued.
Key valuation signals for BSP:DASA3:
EV-to-EBITDA: 5.07 (62% below median its 10-year median of 13.27)
GF Value™: R$1.68 vs. price of R$2.61 (55.4% above fair value)
Industry Position: 66.3% below the Medical Diagnostics & Research median (#16 of 119)
No single metric tells the full story. See the BSP:DASA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diagnosticos da America SA operates as a medical diagnostics company in Brazil. The company offers clinical analysis, diagnostic imaging tests, and patient service centers. It has three operating segments. Outpatient care services and care coordination includes Diagnosis and health management, Hospitals and oncology include Medical and hospital services & Foreign operations include Diagnosis. The majority is from the Hospitals and oncology segment. Geographically, it operates in Brazil and South America (Argentina, Uruguay, Chile and Colombia).
46GF Score
Get the complete analysis for BSP:DASA3
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:DASA3 has been successfully added to your 
